Retrospective Cohort Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 16, 2021; 9(26): 7682-7692
Published online Sep 16, 2021. doi: 10.12998/wjcc.v9.i26.7682
Efficacy of roxadustat in treatment of peritoneal dialysis patients with renal anaemia
Xin-Wang Zhu, Cong-Xiao Zhang, Tian-Hua Xu, Guan-Nan Jiang, Li Yao
Xin-Wang Zhu, Tian-Hua Xu, Guan-Nan Jiang, Li Yao, Department of Nephrology, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China
Cong-Xiao Zhang, Blood Purification Center, The Fourth People’s Hospital of Shenyang, Shenyang 110031, Liaoning Province, China
Author contributions: Zhu XW designed and performed the research; Zhang CX, Xu TH, and Jiang GN contributed to data analysis; Zhu XW wrote the paper; Yao L revised the paper.
Supported by Liaoning Province Key R&D Guidance Program, No. 2019JH8/10300016; and Liaoning Province Grassroots Health and Family Planning Appropriate Technology Promotion Project, No. LHATP-201801.
Institutional review board statement: The protocol of this study was approved by the Ethics Committee of The First Affiliated Hospital of China Medical University. All procedures performed in studies involving human participants were conducted in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Informed consent statement: Written informed consent was obtained from all patients.
Conflict-of-interest statement: All authors have no conflicts of interest related to the manuscript.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li Yao, MD, PhD, Director, Professor, Department of Nephrology, The First Affiliated Hospital of China Medical University, No. 155 Nanjing Bei Street, Heping District, Shenyang 110001, Liaoning Province, China. liyao_cmu@163.com
Received: February 23, 2021
Peer-review started: February 23, 2021
First decision: March 25, 2021
Revised: April 2, 2021
Accepted: July 27, 2021
Article in press: July 27, 2021
Published online: September 16, 2021
Processing time: 198 Days and 22.3 Hours
Core Tip

Core Tip: This was a retrospective study to evaluate the efficacy of roxadustat in the treatment of peritoneal dialysis patients with renal anaemia. A before-and-after self-control design was performed on 31 patients treated with recombinant human erythropoietin (EPO) followed by roxadustat. The haemoglobin compliance rate was 16.1% during the EPO phase and 67.7% during the roxadustat phase. Roxadustat can effectively and safely improve the compliance rate in peritoneal dialysis patients with renal anaemia.